% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/S4-BuyseTest-coef.R
\docType{methods}
\name{S4BuyseTest-coef}
\alias{S4BuyseTest-coef}
\alias{coef,S4BuyseTest-method}
\title{Extract Summary Statistics from GPC}
\usage{
\S4method{coef}{S4BuyseTest}(
  object,
  endpoint = NULL,
  statistic = NULL,
  strata = FALSE,
  cumulative = NULL,
  resampling = FALSE,
  simplify = TRUE,
  ...
)
}
\arguments{
\item{object}{a \code{S4BuyseTest} object, output of \code{\link{BuyseTest}}.}

\item{endpoint}{[character] for which endpoint(s) the summary statistic should be output?
If \code{NULL} returns the summary statistic for all endpoints.}

\item{statistic}{[character] the statistic summarizing the pairwise comparison: \itemize{
\item \code{"netBenefit"}: displays the net benefit, as described in Buyse (2010) and Peron et al. (2016)),
\item \code{"winRatio"}: win ratio or win odds.
\item \code{"favorable"}: proportion strictly in favor of the treatment or Mann-Whitney parameter.
\item \code{"unfavorable"}: proportion in favor of the control.
\item \code{"neutral"}: proportion of neutral pairs.
\item \code{"uninf"}: proportion of uninformative pairs.
\item \code{"count.favorable"}: number of pairs in favor of the treatment.
\item \code{"count.unfavorable"}: number of pairs in favor of the control.
\item \code{"count.neutral"}: number of neutral pairs.
\item \code{"count.uninf"}: number of uninformative pairs.
}
Default value read from \code{BuyseTest.options()}.}

\item{strata}{[character vector] the strata relative to which the statistic should be output.
Can also be \code{"global"} or \code{FALSE} to output the statistic pooled over all strata,
or \code{TRUE} to output each strata-specific statistic.}

\item{cumulative}{[logical] should the summary statistic be cumulated over endpoints?
Otherwise display the contribution of each endpoint.}

\item{resampling}{[logical] should the summary statistic obtained by resampling be output?}

\item{simplify}{[logical] should the result be coerced to the lowest possible dimension?}

\item{...}{ignored.}
}
\value{
When \code{resampling=FALSE} and \code{simplify=FALSE}, a matrix (strata, endpoint).
When \code{resampling=FALSE} and \code{simplify=FALSE}, an array (sample, strata, endpoint).
}
\description{
Extract summary statistics (net benefit, win ratio, ...) from GPC.
}
\details{
\bold{statistic}: with a single endpoint denoted \eqn{Y} and \eqn{X} in the treatment and control group and a threshold of clinical relevance \eqn{\tau}: \itemize{
\item \code{"netBenefit"}: \eqn{P[Y \ge X + \tau] - P[X \ge Y + \tau]}. See Buyse (2010).
\item \code{"winRatio"}: the win ratio \eqn{\frac{P[Y \ge X + \tau]}{P[X \ge Y + \tau]}} or the win odds \eqn{\frac{P[Y \ge X + \tau]+0.5P[|Y - X|<\tau]}{P[X \ge Y + \tau]+0.5P[|Y - X|<\tau]}}. see Wang (2016) and Dong (2019).
\item \code{"favorable"}: \eqn{P[Y \ge X + \tau]} or the Mann-Whitney parameter \eqn{P[Y \ge X + \tau]+0.5P[|Y - X|<\tau]}. See Fay (2018).
\item \code{"unfavorable"}: \eqn{P[Y \le X + \tau]} or \eqn{P[Y \le X + \tau]+0.5P[|Y - X|<\tau]}.
}
The value of the argument \code{add.halfNeutral} used when running \code{\link{BuyseTest}} decides whether \eqn{0.5P[|Y - X|<\tau]} is considered, e.g. whether the win ratio or win odds is output.
}
\references{
On the GPC procedure: Marc Buyse (2010). \bold{Generalized pairwise comparisons of prioritized endpoints in the two-sample problem}. \emph{Statistics in Medicine} 29:3245-3257 \cr
On the Mann-Whitney parameter: Fay, Michael P. et al (2018). \bold{Causal estimands and confidence intervals asscoaited with Wilcoxon-Mann-Whitney tests in randomized experiments}. \emph{Statistics in Medicine} 37:2923-2937 \cr
On the win odds: Dong, G., Hoaglin, D. C., Qiu, J., Matsouaka, R. A., Chang, Y. W., Wang, J., & Vandemeulebroecke, M. (2019). \bold{The Win Ratio: On Interpretation and Handling of Ties}. \emph{Statistics in Biopharmaceutical Research}, 12(1), 99â€“106. https://doi.org/10.1080/19466315.2019.1575279 \cr
On the win ratio: D. Wang, S. Pocock (2016). \bold{A win ratio approach to comparing continuous non-normal outcomes in clinical trials}. \emph{Pharmaceutical Statistics} 15:238-245
}
\author{
Brice Ozenne
}
\keyword{method}
